Nanomedicine-based Chemo-Immunotherapy for the Treatment of Pediatric Brain Cancer

在这个项目中，我们建议建立和验证髓母细胞瘤的同基因小鼠模型，并了解负载ICD诱导药物的肿瘤pH敏感NM调节肿瘤免疫环境对抗MB的潜力。为了实现这些目标，我们设法实现了以下研究成果-建立并验证了髓母细胞瘤(MB)的同基因小鼠模型-Robert Wechsler-Reya博士在美国加利福尼亚州Sanford Burnham Prebys医学发现研究所的实验室建立了几个MB同基因模型。合作研究人员之一(Co-I)Sabina Quader博士可以成功地启动与Wechsler-Reya博士的研究合作。通过这次合作，我们在实验室里创造了一个同基因的亚甲基蓝小鼠模型。我们认为这是我们MB相关研究的一个重大进展，因为建立同基因小鼠模型对于抗MB的免疫相关研究至关重要。收集初步研究结果-我们成功地利用加载ICD诱导药物的肿瘤pH敏感NM对抗MB同基因模型进行了初步研究。根据这些研究的结果，我们现在正在进入下一阶段的研究，在那里我们正在考虑使用免疫检查点抑制剂的可能性。

For this project, we proposed to generate and validate a syngeneic mouse model of medulloblastoma and understand the potential of a tumor pH-sensitive NM loaded with ICD-inducing drug modulating tumor immune environment against MB. Towards these aims, we managed to achieve the following research outcomes-Generate and validate a syngeneic mouse model of medulloblastoma (MB) - Dr. Robert Wechsler-Reya's laboratory at Sanford Burnham Prebys Medical Discovery Institute, CA, United States, established several MB syngeneic models. One of the collaborating investigators (Co-I), Dr. Sabina Quader, could successfully initiate a research collaboration with Dr. Wechsler-Reya. Through this collaboration we created a syngeneic mouse model of MB in our laboratory. We consider this a significant advancement in our MB-related research, as developing a syngeneic mouse model is critical for immune-related studies against MB.Collect preliminary research results using tumor pH-sensitive NM loaded with ICD-inducing drug against MB syngeneic model- We have successfully completed our preliminary research studies using tumor pH-sensitive NM loaded with ICD-inducing drug against MB syngeneic model. Based on the results of these studies, we are now moving on to the next phase of studies, where we are considering examining the potential of using immune checkpoint inhibitors.